Farydak Clinical Development Timeline
Chronicle of the development and review of Novartis' histone deacetylase inhibitor panobinostat.
You may also be interested in...
Round-up of late summer applications recently submitted to US FDA, adapted from the Pink Sheet FDA Performance Tracker's User Fee Goal Dates chart.
Recent submissions include what could be the fourth novel agent approved under the RTOR pilot.
Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.